Stone, J. H., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., … Specks, U. (2011). Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare? In ARTHRITIS AND RHEUMATISM (Vol. 63, pp. S946–S947). Chicago, IL: WILEY-BLACKWELL.

Stone, John H., Peter A. Merkel, Philip Seo, Robert Spiera, Carol A. Langford, Gary S. Hoffman, Cees G. M. Kallenberg, et al. “Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare?” In ARTHRITIS AND RHEUMATISM, 63:S946–47. WILEY-BLACKWELL, 2011.

Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare? In: ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL; 2011. p. S946–7.

Stone, John H., et al. “Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare?” ARTHRITIS AND RHEUMATISM, vol. 63, no. 10, WILEY-BLACKWELL, 2011, pp. S946–47.

Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Fessler BJ, Tchao N, Webber L, Ding L, Sejismundo LP, Mieras K, Ikle D, Phippard DJ, Jepson B, Lail A, Asare A, Lim N, Mueller M, Brunetta P, Allen NB, Fervenza F, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U. Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare? ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL; 2011. p. S946–S947.